REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule MEK 1/2 inhibitor. The platform analyzed cellular models of APC gene loss-the root cause of FAP-to identify compounds ...

Ayna joins Antag with extensive experience in obesity and clinical pharmacology. She most recently served as Senior Principal ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Neuroscientists have developed a new treatment approach for a language disorder that combines traditional speech therapy with noninvasive electrical stimulation of the brain. Brain stimulation helped ...

Sylvie Grégoire, Chair of Abivax Board of Directors, commented: “We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical ...

Bayer and Vividion Therapeutics to present latest research on their advancing oncology portfolio at AACR 2025 annual meeting: Berlin, Germany Wednesday, April 23, 2025, 10:00 Hrs ...

A proof-of-concept study will test VAS-101, a topical gel using the turmeric extract curcumin, in sickle cell disease (SCD) ...

Oral hormone therapy may benefit heart health in menopausal women. A new analysis of data from the Women's Health Initiative found that estrogen-based oral hormone therapy had a long-term beneficial ...

Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary said on Tuesday that the agency plans to remove ...

There are four emerging powerhouses in China biotech: Henlius, BeiGene, Innovent and ZaiLab. All were founded in the 2010s, ...

Shares of Aclaris Therapeutics were trading higher after the company said regulators had cleared its new drug application for a trial of ATI-052, its potential treatment for immuno-inflammatory ...

Plus, anti-violence activist meets with Millbourne mayor, new trial takes new approach to advanced prostate cancer, Aqua, ...